Stannsoporfin - InfaCare Pharmaceuticals

Drug Profile

Stannsoporfin - InfaCare Pharmaceuticals

Alternative Names: Sn-mesoporphyrin; Stanate; tin-mesoporphyrin; Torcan

Latest Information Update: 27 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Rockefeller University
  • Developer InfaCare Pharmaceutical Corporation; National Hospital of Pediatrics
  • Class Antirheumatics; Heavy metals; Hepatoprotectants; Mesoporphyrins
  • Mechanism of Action Decyclizing heme oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Hyperbilirubinaemia

Most Recent Events

  • 25 Sep 2017 InfaCare Pharmaceutical Corporation has been acquired by Mallinckrodt plc
  • 04 Aug 2017 Preregistration for Hyperbilirubinaemia (In neonates) in USA prior to August 2017 (IM)
  • 04 Aug 2017 InfaCare anticipates the approval of Stannsoporfin in USA in the first half of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top